New cocktail aims to make liver cancer operable

NCT ID NCT06405061

Terminated Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of chemotherapy, immunotherapy, and a targeted drug given directly into the liver's blood supply to shrink tumors in people with liver cancer that may be removable with surgery. The goal is to see if this approach can make surgery more effective and reduce the chance of cancer coming back. About 40 adults with a specific stage of liver cancer will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADEBRELIMAB are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADEBRELIMAB HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China
Third Central Hospital of Tianjin

Tianjin, Tianjin Municipality, China
Tianjin Cancer Hospital Airport Hospital

Tianjin, Tianjin Municipality, 300308, China
Tianjin First Central Hospital

Tianjin, Tianjin Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.